Effects of Probiotic Supplementation on Pancreatic β-cell Function and C-reactive Protein in Women with Polycystic Ovary Syndrome: A Randomized Double-blind Placebo-controlled Clinical Trial

Tanaz Shoaei, Motahar Heidari-Beni, Hatav Ghasemi Tehrani, Awat Feizi, Ahmad Esmaillzadeh, Gholamreza Askari, Tanaz Shoaei, Motahar Heidari-Beni, Hatav Ghasemi Tehrani, Awat Feizi, Ahmad Esmaillzadeh, Gholamreza Askari

Abstract

Background: Polycystic ovary syndrome (PCOS) is a polygenic endocrine disorder in women of reproductive age that lead to infertility. The aim of this study was to investigate the effects of probiotic on pancreatic β-cell function and C-reactive protein (CRP) in PCOS patients.

Methods: This randomized double-blind placebo-controlled clinical trial was conducted among 72 women aged 15-40 years old diagnosed with PCOS. Participants were randomly assigned to two groups receiving: (1) Probiotic supplements (n = 36), (2) placebo (n = 36) for 8-week. Fasting blood samples were taken at baseline and after 8-week of intervention.

Results: Probiotic supplementation, compare with placebo, reduced fasting blood sugar (-4.15 ± 2.87 vs. 2.57 ± 5.66 mg/dL, respectively P = 0.7), serum insulin levels in crude model (-0.49 ± 0.67 vs. 0.34 ± 0.82 μIU/mL, respectively, P = 0.09), homeostasis model of assessment-insulin resistance score (-0.25 ± 0.18 vs. -0.05 ± 0.18, respectively, P = 0.14) nonsignificantly. Serum insulin levels after adjustment with covariates reduced significantly in probiotic group (P = 0.02). We did not found any significant differences in mean changes of CRP between groups (-0.25 ± 0.18 vs. -0.05 ± 0.18, respectively, P = 0.14).

Conclusions: A 8-week multispecies probiotics supplementation had nonsignificantly beneficial effect on pancreatic β-cell function and CRP in PCOS patients. After adjustment for some covariates, serum insulin changes were significantly different between groups.

Keywords: C-reactive protein; pancreatic β-cell function; polycystic ovary syndrome; probiotic supplementation.

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Summary of patient flow diagram, individuals received 500 mg probiotic supplements daily, polycystic ovary syndrome

References

    1. Pasquali R, Gambineri A. Polycystic ovary syndrome: A multifaceted disease from adolescence to adult age. Ann N Y Acad Sci. 2006;1092:158–74.
    1. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008;23:462–77.
    1. Wehr E, Möller R, Horejsi R, Giuliani A, Kopera D, Schweighofer N, et al. Subcutaneous adipose tissue topography and metabolic disturbances in polycystic ovary syndrome. Wien Klin Wochenschr. 2009;121:262–9.
    1. Dunaif A. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocr Rev. 1997;18:774–800.
    1. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: Etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7:219–31.
    1. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest. 1995;96:520–7.
    1. Cussons AJ, Stuckey BG, Watts GF. Cardiovascular disease in the polycystic ovary syndrome: New insights and perspectives. Atherosclerosis. 2006;185:227–39.
    1. Boyle JA, Cunningham J, O’Dea K, Dunbar T, Norman RJ. Prevalence of polycystic ovary syndrome in a sample of Indigenous women in Darwin, Australia. Med J Aust. 2012;196:62–6.
    1. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25:544–51.
    1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: Hormonal and metabolic profile. J Clin Endocrinol Metab. 1999;84:4006–11.
    1. Setji TL, Brown AJ. Polycystic ovary syndrome: Update on diagnosis and treatment. Am J Med. 2014;127:912–9.
    1. Costello MF, Misso ML, Wong J, Hart R, Rombauts L, Melder A, et al. The treatment of infertility in polycystic ovary syndrome: A brief update. Aust N Z J Obstet Gynaecol. 2012;52:400–3.
    1. Lindström J, Neumann A, Sheppard KE, Gilis-Januszewska A, Greaves CJ, Handke U, et al. Take action to prevent diabetes – The IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res. 2010;42(Suppl 1):S37–55.
    1. Yadav H, Jain S, Sinha PR. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition. 2007;23:62–8.
    1. Alokail MS, Sabico S, Al-Saleh Y, Al-Daghri NM, Alkharfy KM, Vanhoutte PM, et al. Effects of probiotics in patients with diabetes mellitus type 2: Study protocol for a randomized, double-blind, placebo-controlled trial. Trials. 2013;14:195.
    1. Allen SJ, Jordan S, Storey M, Thornton CA, Gravenor M, Garaiova I, et al. Dietary supplementation with lactobacilli and bifidobacteria is well tolerated and not associated with adverse events during late pregnancy and early infancy. J Nutr. 2010;140:483–8.
    1. Tanriover MD, Aksoy DY, Unal S. Use of probiotics in various diseases: Evidence and promises. Pol Arch Med Wewn. 2012;122(Suppl 1):72–7.
    1. Harisa GI, Taha EI, Khalil AF, Salem MM. Oral Administration of Lactobacillus acidophilus restores nitric oxide level in diabetic rats. Aust J Basic Appl Sci. 2009;3:2963–9.
    1. Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis. World J Gastroenterol. 2013;19:6911–8.
    1. Musmar S, Afaneh A, Mo’alla H. Epidemiology of polycystic ovary syndrome: A cross sectional study of university students at An-Najah national university-Palestine. Reprod Biol Endocrinol. 2013;11:47.
    1. Pisprasert V, Ingram KH, Lopez-Davila MF, Munoz AJ, Garvey WT. Limitations in the use of indices using glucose and insulin levels to predict insulin sensitivity: Impact of race and gender and superiority of the indices derived from oral glucose tolerance test in African Americans. Diabetes Care. 2013;36:845–53.
    1. Bargiota A, Diamanti-Kandarakis E. The effects of old, new and emerging medicines on metabolic aberrations in PCOS. Ther Adv Endocrinol Metab. 2012;3:27–47.
    1. Diamant M, Blaak EE, de Vos WM. Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes? Obes Rev. 2011;12:272–81.
    1. Caesar R, Fåk F, Bäckhed F. Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism. J Intern Med. 2010;268:320–8.
    1. Cani PD, Delzenne NM. The gut microbiome as therapeutic target. Pharmacol Ther. 2011;130:202–12.
    1. Delzenne NM, Cani PD. Nutritional modulation of gut microbiota in the context of obesity and insulin resistance: Potential interest of prebiotics. Int Dairy J. 2010;20:277–80.
    1. Ley RE. Obesity and the human microbiome. Curr Opin Gastroenterol. 2010;26:5–11.
    1. Tuohy KM, Gougoulias C, Shen Q, Walton G, Fava F, Ramnani P. Studying the human gut microbiota in the trans-omics era – Focus on metagenomics and metabonomics. Curr Pharm Des. 2009;15:1415–27.
    1. Nitert MD, Barrett HL, Foxcroft K, Tremellen A, Wilkinson S, Lingwood B, et al. SPRING: An RCT study of probiotics in the prevention of gestational diabetes mellitus in overweight and obese women. BMC Pregnancy Childbirth. 2013;13:50.
    1. Laitinen K, Poussa T, Isolauri E Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota Group. Probiotics and dietary counselling contribute to glucose regulation during and after pregnancy: A randomised controlled trial. Br J Nutr. 2009;101:1679–87.
    1. Asemi Z, Zare Z, Shakeri H, Sabihi SS, Esmaillzadeh A. Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. Ann Nutr Metab. 2013;63:1–9.
    1. Asemi Z, Jazayeri S, Najafi M, Samimi M, Mofid V, Shidfar F, et al. Effects of daily consumption of probiotic yoghurt on inflammatory factors in pregnant women: A randomized controlled trial. Pak J Biol Sci. 2011;14:476–82.
    1. Zhang JW, Du P, Chen DW, Cui L, Ying CM. Effect of viable Bifidobacterium supplement on the immune status and inflammatory response in patients undergoing resection for colorectal cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 2010;13:40–3.
    1. Anderson AD, McNaught CE, Jain PK, MacFie J. Randomised clinical trial of synbiotic therapy in elective surgical patients. Gut. 2004;53:241–5.
    1. Hatakka K, Martio J, Korpela M, Herranen M, Poussa T, Laasanen T, et al. Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis – A pilot study. Scand J Rheumatol. 2003;32:211–5.
    1. Ranganathan N, Friedman EA, Tam P, Rao V, Ranganathan P, Dheer R. Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: A 6-month pilot scale trial in Canada. Curr Med Res Opin. 2009;25:1919–30.
    1. Lye HS, Kuan CY, Ewe JA, Fung WY, Liong MT. The improvement of hypertension by probiotics: Effects on cholesterol, diabetes, renin, and phytoestrogens. Int J Mol Sci. 2009;10:3755–75.
    1. Sadrzadeh-Yeganeh H, Elmadfa I, Djazayery A, Jalali M, Heshmat R, Chamary M. The effects of probiotic and conventional yoghurt on lipid profile in women. Br J Nutr. 2010;103:1778–83.
    1. Introduction of a Qualified Presumption of Safety [QPS] approach for assessment of selected microorganisms referred to EFSA. Opinion of the Scientific Committee. The EFSA J. 2007;587:1–16.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren